Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia

scientific article published on 2 April 2015

Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1177/1358863X15574321
P698PubMed publication ID25835349

P2093author name stringEhrin J Armstrong
Ezra A Amsterdam
John R Laird
Gagan D Singh
Debbie C Chen
P2860cites workEndothelial dysfunction: the first step toward coronary arteriosclerosisQ37395620
Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia.Q37620353
Potential vascular mechanisms of ramipril induced increases in walking ability in patients with intermittent claudicationQ38438066
Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trialQ38456532
Optimal medical therapy predicts amputation-free survival in chronic critical limb ischemiaQ39357910
Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial diseaseQ39671945
Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protectionQ40630962
Vascular hospitalization rates and costs in patients with peripheral artery disease in the United States.Q44950795
Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) RegistryQ46215474
Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery diseaseQ46638911
Mortality over a period of 10 years in patients with peripheral arterial diseaseQ46786119
Quality of care among patients undergoing lower extremity revascularization.Q51114226
Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo.Q54092413
Critical limb ischemia.Q55052558
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)Q56287926
The central role of the propensity score in observational studies for causal effectsQ56882400
Epidemiology, classification, and modifiable risk factors of peripheral arterial diseaseQ24681271
The morbidity and mortality following a diagnosis of peripheral arterial disease: long-term follow-up of a large databaseQ24810579
Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extensionQ28189678
Cardioprotective medication is associated with improved survival in patients with peripheral arterial diseaseQ28195786
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trialQ28214393
Peripheral arterial disease detection, awareness, and treatment in primary careQ28216456
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patientsQ29619542
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering CommitteeQ29620666
The global pandemic of peripheral artery disease.Q30352611
Angiotensin-converting enzyme inhibition improves defective angiogenesis in the ischemic limb of spontaneously hypertensive ratsQ31027565
Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE).Q31956512
Telmisartan, ramipril, or both in patients at high risk for vascular eventsQ33156143
Role of bradykinin, nitric oxide, and angiotensin II type 2 receptor in imidapril-induced angiogenesisQ33310785
Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease.Q34297015
Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysisQ34361910
ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society fQ34503123
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE InvestigatorsQ34539986
Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004.Q35116739
The potential role of angiotensin-converting enzyme inhibition in peripheral arterial diseaseQ35763822
ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for VasculQ36426489
Gender-related variation in the clinical presentation and outcomes of critical limb ischemiaQ37205015
P433issue3
P921main subjectcirculatory systemQ11068
P304page(s)237-244
P577publication date2015-04-02
P1433published inVascular MedicineQ7916445
P1476titleAngiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia
P478volume20

Reverse relations

cites work (P2860)
Q576211772017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)
Q97094318Angiotensin converting enzyme inhibitors and angiotensin receptor blockers have no effect on the outcomes of endovascular revascularization in tibial arterial occlusive disease
Q90489664Atherosclerosis knowledge - diagnosis and management in primary care
Q38850458Contemporary evaluation and management of lower extremity peripheral artery disease.
Q52717834Interventions for lower extremity peripheral artery disease.
Q47700735Long-term mortality benefit of renin-angiotensin system inhibitors in patients with chronic limb-threatening ischemia undergoing vascular intervention
Q38685935Long-term outcomes in patients with critical limb ischemia and heart failure with preserved or reduced ejection fraction
Q38834990Medical Therapy in Peripheral Artery Disease and Critical Limb Ischemia
Q38574304Meta-analysis on autologous stem cell transplantation in the treatment of limb ischemic.
Q96304410Rivaroxaban in patients with ischaemic chronic cardiomyopathy and obstructive peripheral arterial disease: rationale for treatment and results
Q54282563Vascular specialist response to Medicare Evidence Development Coverage Advisory Committee (MEDCAC) panel on peripheral artery disease of the lower extremities.
Q44547282Vascular specialist response to medicare evidence development coverage advisory committee (MEDCAC) panel on peripheral artery disease of the lower extremities

Search more.